Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence 2024, the annual meeting of the American College of Rheumatology BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today... Read More

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus... Read More

BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral... Read More

BURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or... Read More

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company,... Read More

BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26 th Annual Global Investment Conference, which is... Read More

Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma (PTCL) Advancing Toward Initial Enrollment in Q3 2024;... Read More

Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL... Read More

BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or... Read More

Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th 17 cells into anti-inflammatory T reg cells Publication confirms and extends understanding of ITK inhibition mechanism of action and its potential in inflammatory autoimmune and allergic diseases Data published by leading researchers from Cornell University in peer-reviewed journal Science Signaling BURLINGAME,... Read More

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York... Read More

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefined Deep Response Threshold Conference call today at 4:30 p.m. ET / 1:30 p.m. PT... Read More

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or... Read More

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001... Read More

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized,... Read More

Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potential to address the need for new treatments for... Read More

BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free... Read More

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and... Read More

BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma. Soquelitinib, the Company’s lead ITK inhibitor candidate, is expected to advance into a Phase 3 registrational clinical trial in... Read More

BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio... Read More

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences to her family, colleagues and community. “Edith had a distinguished career in healthcare, spanning patient care, education, clinical... Read More

Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need for new treatments for peripheral T cell lymphoma (PTCL) Results confirmed patient eligibility requirements and endpoints planned... Read More

Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment New data from soquelitinib Phase 1 T cell lymphoma trial accepted for presentation at the 65th ASH Annual Meeting and Exposition New publications highlight therapeutic potential of ITK inhibition in solid tumors and multiple autoimmune and allergic... Read More

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL), at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from... Read More

Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases Soquelitinib’s unique mechanism of action inhibited the production of Th2 and Th17 cells, providing upstream attenuation of several validated cytokine targets such as IL-4, IL-5, IL-13, IL-17 BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) --... Read More

BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or... Read More

Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a... Read More

Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and solid tumors Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical... Read More

BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or... Read More

Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response to hematologic and solid tumors Soquelitinib shown to increase infiltration of cancer killing T cells with greater potency and less resistance due to exhaustion BURLINGAME, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced... Read More

Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic RCC in combination with anti-CTLA-4 and anti-PD-1 therapies BURLINGAME, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical... Read More

Data supported CPI-818’s novel immunotherapy mechanism of action and its potential to provide a platform approach to a broad range of solid and hematological cancers Laboratory and clinical data demonstrated induction of host Th1 immune response that is independent of checkpoint inhibition Company plans to meet with FDA during... Read More

BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Healthcare Conference, which is being held in New York from June 7-9. The presentation will... Read More

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland. “We continue to make strong progress in the development of ITK... Read More

Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial... Read More

BURLINGAME, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on May 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2023 financial results. The conference call can be accessed by dialing 1-844-825-9789 or 1-412-317-5180... Read More

Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased T cell cytolytic capacity and reduction of T cell exhaustion Enrollment continues in Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma, including use of minimum absolute lymphocyte count (ALC)... Read More

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10 th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data... Read More

New CPI-818 Predictive Biomarker Enables Selection of Lymphoma Patients Most Likely to Benefit from Treatment Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical... Read More

BURLINGAME, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 28, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2022 financial results. The conference call can be accessed by dialing 1-844-825-9789 or... Read More

BURLINGAME, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL. The data demonstrates that in a murine syngeneic CT26 colon cancer... Read More

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and Opportunistic Infections Research partners from UCSF and Vitalant to continue studying potential for ITK inhibition to be developed within antiproliferative and “block-and-lock” HIV cure strategies BURLINGAME, Calif., Feb. 21, 2023... Read More

Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast... Read More